First Time Loading...

Pieris Pharmaceuticals Inc
NASDAQ:PIRS

Watchlist Manager
Pieris Pharmaceuticals Inc Logo
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Watchlist
Price: 11.08 USD -1.42% Market Closed
Updated: May 4, 2024

Pieris Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pieris Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Revenue
$42.8m
CAGR 3-Years
13%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

See Also

What is Pieris Pharmaceuticals Inc's Revenue?
Revenue
42.8m USD

Based on the financial report for Dec 31, 2023, Pieris Pharmaceuticals Inc's Revenue amounts to 42.8m USD.

What is Pieris Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 5Y
8%

Over the last year, the Revenue growth was 65%. The average annual Revenue growth rates for Pieris Pharmaceuticals Inc have been 13% over the past three years , 8% over the past five years .